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Abstract
Background: Although plasma fibrinogen levels are related to cardiovascular risk, data regarding the role of
fibrinogen genetic variation in myocardial infarction (MI) or coronary artery disease (CAD) etiology remain
inconsistent. The purpose of the present study was to investigate the effect of fibrinogen A (FGA), fibrinogen B (FGB)
and fibrinogen G (FGG) gene SNPs and haplotypes on susceptibility to CAD in a homogeneous Greek population.
Methods: We genotyped for rs2070022, rs2070016, rs2070006 in FGA gene, the rs7673587, rs1800789, rs1800790,
rs1800788, rs1800787, rs4681 and rs4220 in FGB gene and for the rs1118823, rs1800792 and rs2066865 SNPs in FGG
gene applying an arrayed primer extension-based genotyping method (APEX-2) in a sample of CAD patients
(n = 305) and controls (n = 305). Logistic regression analysis was used to calculate odds ratios (ORs) and 95%
confidence intervals (CIs), before and after adjustment for potential confounders.
Results: None of the FGA and FGG SNPs and FGA, FGB, FGG and FGA-FGG haplotypes was associated with disease
occurrence after adjustment. Nevertheless, rs1800787 and rs1800789 SNPs in FGB gene seem to decrease the risk of
CAD, even after adjustment for potential confounders (OR = 0.42, 95%CI: 0.19-0.90, p = 0.026 and OR = 0.44, 95%
CI:0.21-0.94, p = 0.039, respectively).
Conclusions: FGA and FGG SNPs as well as FGA, FGB, FGG and FGA-FGG haplotypes do not seem to be important
contributors to CAD occurrence in our sample. On the contrary, FGB rs1800787 and rs1800789 SNPs seem to confer
protection to disease onset lowering the risk by about 50% in homozygotes for the minor alleles.
Background
Fibrinogen (Factor I) constitutes a water-soluble glyco-
protein with a molecular weight of 340 kDa that is
mainly synthesized in hepatocytes. It is a major factor of
the coagulation system that participates in the process
of hemostasis in two discrete pathways: Primarily, it is
part of the final common pathway of the coagulation
cascade. Secondarily, fibrinogen is bound to platelet
GpIIb/IIIa membrane receptors and forms a web that
provides stability to the newly-formed thrombus [1,2].
Apart from its role in coagulation reactions, fibrinogen
participates in atherosclerosis development by
promoting the adhesion of platelets and white blood
cells to the endothelial surface [3-5] by promoting mus-
cle cell proliferation and migration, as well as by modu-
lating the binding of plasmin with its receptor [1].
Fibrinogen levels in plasma have been associated with
coronary artery disease and myocardial infarction risk in
prospective studies [6-9]. However, it is still unclear
whether increased fibrinogen levels are causal to disease
development or just a secondary phenomenon.
Fibrinogen circulates in plasma as a dimer, composed
of three pairs of polypeptide chains denoted Aa (alpha),
Bb (beta) and g (gamma) encoded by fibrinogen alpha
(FGA), beta (FGB) and gamma (FGG) genes respectively
that are clustered on chromosome 4q31[10]. A variant
of g chain, named g’ is derived by alternate splicing of
* Correspondence: itheodoraki@gmail.com
1Harokopio University of Athens, Department of Dietetics and Nutritional
Science, El Venizelou 70, 17671, Athens, Greece
Theodoraki et al. BMC Medical Genetics 2010, 11:28
http://www.biomedcentral.com/1471-2350/11/28
© 2010 Theodoraki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.the primary mRNA [11]. The genes are arranged in
order FGG-FGA-FGB,w i t h i na5 0k br e g i o n ,w i t ht h e
transcriptional direction of FGG and FGA opposite to
that of FGB [10].
The study of SNPs and haplotypes of fibrinogen genes
in relation to coronary artery disease (CAD) and myo-
cardial infarction (MI) occurrence has yielded to date
inconsistent results. Some investigators have reported
associations between fibrinogen gene SNPs or haplo-
types with MI or CAD occurrence [12-14], whereas
other studies have not replicated these associations
[15-18].
Although numerous studies have been performed,
scarce data concerning the role of fibrinogen gene SNPs
or haplotypes in the Greek population are available.
Therefore, we performed a retrospective case-control
study involving 305 patients presenting with either CAD
or acute coronary syndrome (ACS) and 305 healthy con-
trol subjects in order to investigate the impact of FGA,
FGB and FGG gene SNPs and haplotypes on disease
occurrence.
Methods
Study participants were recruited from 3 hospitals
found in the area of Athens. Cases were subjects pre-
senting with either ACS or stable CAD defined as
>50% stenosis in at least one of the three main coron-
ary vessels assessed by coronary angiography. ACS was
defined as acute MI or unstable angina corresponding
to class III of the Braunwald classification [19]. ACS
patients have also undergone coronary angiography
examination that verified the presence of significant
stenosis.
Controls were subjects with negative coronary angio-
graphy findings, or negative stress test, or subjects with-
out symptoms of disease that were admitted at the same
hospitals as cases and were free of any cardiovascular
disease, cancer, or inflammatory diseases. Moreover, we
excluded subjects with renal or hepatic disease from
both study groups. The bioethics committee of Haroko-
pio University approved the study and all participants
gave their informed consent.
Regarding the clinical characteristics of study subjects,
hypercholesterolemia was defined as total cholesterol
levels greater than 200 mg/dl or use of hypolipidemic
medication, while hypertension was defined as blood
pressure levels greater than 140/90 mm Hg or use of
antihypertensive medication. We classified as diabetics
subjects with blood glucose levels greater than 126 mg/
dl or subjects that were under special diet or treatment.
Finally, positive family history of myocardial infarction
was defined as the presence of myocardial infarction in
first degree male relatives at age < 55 years or in first
degree female relatives at age <65 years.
Altogether 13 tag SNPs were genotyped for each indi-
vidual in case-control samples. Carlson’s algorithm was
applied for SNP selection using Tagger implementation
introduced in Haploview [20], where HapMap CEU was
used as a reference population (with thresholds r
2 ≥ 0.8
and minor allele frequency (MAF) ≥ 10%) [21]. SNPs
were selected for each gene including 10 kb of both
upstream and downstream sequences. A SNP rs1800787
in FGB gene was force-included to Tagger selection
referring to the previously published data. Selected
SNPs, as well as their location in the gene, are presented
in Table 1.
Genomic DNA was extracted from whole blood using
the salting-out method [22]. Genotyping was performed
using an arrayed primer extension-based genotyping
method (APEX-2). This method allows multiplex DNA
amplification and detection of SNPs on microarrays via
four-color single-base primer extension [23].
The standard chi-square test was used to test for
deviations from Hardy-Weinberg equilibrium and to
evaluate the differences in genotype distributions
between cases and controls.
The odds ratios (ORs) were calculated using logistic
regression under the assumption of the additive, domi-
nant and recessive models. Logistic regression including
age, sex, and the presence of diabetes, hypertension,
hypercholesterolemia and smoking as covariates was
used to calculate adjusted ORs. Analysis of single SNPs
effects was performed using PLINK 1.05 [24].
Haplotypes were constructed for each gene separately
and for FGG-FGA genes. We did not consider FGA-
FGG-FGB haplotypes in the analysis due to weak LD
(Linkage Disequilibrium) between FGA-FGG and FGB
variants. THESIAS software [25] was used to calculate
haplotype frequencies in cases and controls as well as
Table 1 TagSNPs for the FGA, FGB and FGG genes.
Gene tagSNP Alleles
a SNP location AA change
FGA rs2070022 C>T 3’ UTR -
rs2070016 C>T Intron 2 -
rs2070006 A>G 5’ upstream -
FGB rs7673587 C>T 5’ upstream -
rs1800789 G>A 5’ upstream -
rs1800790 G>A 5’ upstream -
rs1800788 C>T 5’ upstream -
rs1800787 C>T 5’ upstream -
rs4681 C>T Exon 7 Y375Y
rs4220 G>A Exon 8 R478K
FGG rs1118823 T>A 3’ downstream -
rs2066865 G>A 3’ downstream -
rs1800792 T>C 5’ upstream -
aAlleles are depicted from the coding strand for all SNPs except of rs2070022,
rs2070016, rs2070006, rs2066865 and rs1800792 that are depicted from the
non-coding one.
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after adjustment for the aforementioned covariates using
the most common haplotype as a reference. LD mea-
sures (r
2 and D’) between SNPs were calculated using
Haploview [20]. D’ values are given in Figure 1. All p-
values are based on two-sided tests and compared to a
significance level of 5%.
Power analysis was performed using Quanto 1.2
software.
Results
Table 2 summarises the characteristics of 305 CAD and
ACS cases and 305 control subjects. The two study
groups differed in a predictable manner, i.e. cases exhib-
ited a higher prevalence of risk factors such as hyperch-
olesterolemia, hypertension, diabetes and smoking.
Patients presenting ACS represented 62.6% of all cases.
Mean age, as well as the percentage of male subjects
was lower among controls than in cases. BMI did not
present statistically significant differences between the
two study groups. Although hypercholesterolemia was
most common among cases, total cholesterol and LDL
levels are higher in the control group, due to the less
frequent use of hypolipidemic medication.
All SNPs were in Hardy-Weinberg equilibrium except
for FGB rs7673587 and rs1800788 SNPs (p < 0.05) that
were excluded from subsequent analysis.
Logistic regression analysis was performed for FGA,
FGB and FGG gene SNPs separately, under the assump-
tion of the additive, dominant and recessive models.
ORs and 95% CIs were calculated before and after
adjustment for age, sex and the presence of hypercholes-
terolemia, hypertension, diabetes and smoking. Four
SNPs were nominally associated with disease in at least
one model of inheritance (Table 3).
Thus, carriers of one minor allele of rs2070006 in
FGA gene exhibited an OR of 1.26 (95% CI:0.99-1.59,
p = 0.055), that after adjustment was 1.26 (95% CI:0.98-
1.63, p = 0.081). When carriers of the minor allele were
grouped together, i.e. when modeled dominantly, the
unadjusted OR was 1.51 (95% CI: 1.09-2.09, p = 0.013),
while after adjustment OR was 1.39 (95% CI:0.97-1.99,
p = 0.077).
Figure 1 Linkage disequilibrium structure.D ’ values between SNPs in FGA, FGB and FGG genes.
Table 2 General characteristics of patients and controls
included in our study.
Subject characteristics Cases
(n = 305)
Controls
(n = 305)
P-value
Stable CAD (%) 37.4 -
ACS (%) 62.6 -
Age (years) 63.14 ± 11.41 60.37 ± 14.86 0.011
Male sex (%) 81.6 70.2 0.001
BMI (kg/m
2) 27.9 ± 3.8 28.2 ± 4.6 0.403
Hypercholesterolemia (%) 76.9 59.0 <0.001
Diabetes (%) 32.4 15.1 <0.001
Hypertension (%) 71.7 58.8 0.001
Family history of MI (%) 28.0 16.7 0.001
Current or former smoking (%) 74.2 61.0 <0.001
Total cholesterol (mg/dl) 197.7 ± 47.7 214.4 ± 40.4 <0.001
LDL cholesterol (mg/dl) 126.6 ± 41.6 141.2 ± 36.4 <0.001
HDL cholesterol (mg/dl) 50.6 ± 12.6 45.8 ± 14.3 <0.001
Triglycerides (mg/dl) 144.2 ± 66.8 118.1 ± 65.6 <0.001
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rs1800789, were associated with disease occurrence in
the recessive model, and the association remained signif-
icant after adjustment for the confounding variables (OR
= 0.47, 95% CI:0.24-0.92, p = 0.026 and OR = 0.50, 95%
CI:0.27-0.96, p = 0.039, respectively). The association of
those SNPs with disease was significant even after
further adjustment for obesity (BMI > 27) (OR = 0.40,
95% CI:0.18-0.18, p = 0.023 and OR = 0.38, 95%
CI:0.17-0.85, p = 0.019, respectively).
Rs2066865 in FGG gene showed borderline association
with CAD. For carriers of one minor allele, the unad-
justed OR was 1.31 (95% CI:0.99-1.75, p = 0.062), while
after adjustment it was 1.32 (95% CI:0.97-1.80, p =
0.077). Results did not differ much when the dominant
model was considered. No other SNP in FGA, FGB and
FGG genes was associated with disease occurrence.
In Table 4 the inferred haplotypes for FGA, FGB, FGG
and FGA-FGG SNPs with frequency >5% are presented.
In Table 5 the ORs and 95% CIs are presented for each
haplotype before and after adjustment for the same con-
founding variables as in the case of single SNPs. We
used the most common haplotype as a reference cate-
gory. FGA-FGG H3 haplotype TGATTA bearing the 2
minor alleles of rs2070006 and rs2066865 was associated
with CAD in the unadjusted analysis (OR = 1.42, 95%
CI:1.02-1.98, p = 0.040), but after adjustment for con-
founding factors the statistical significance was lost (OR
= 1.38, 95% CI: 0.94-2.02, p = 0.098).
Further adjustment for lipid levels, i.e. total choles-
terol, LDL cholesterol and HDL cholesterol, did not sig-
nificantly affect our results concerning both single SNP
and haplotype effects.
Discussion
Evidence from epidemiologic studies and meta-analyses
suggests that increased plasma fibrinogen levels are
related to increased coronary artery disease risk [6].
Despite the existence of numerous studies that support
an association between plasma fibrinogen levels and
certain SNPs or haplotypes [13,15,26-28], data linking
the latter with CAD occurrence still remain
controversial.
In the present study we used a tagSNP approach to
evaluate the role of genetic variation across FGA, FGB
and FGG genes in the occurrence of coronary artery dis-
ease in a homogeneous Greek population sample of 305
patients and 305 controls. CAD was defined as either
presence of angiographically proven significant stenosis
in coronary vessels or ACS.
The allele frequencies in controls, observed in our
study, were similar to the ones reported for HapMap
CEU reference population. Rs2070006 and rs2066865
SNPs in FGA and FGG genes respectively were nomin-
ally associated with increased risk of CAD both in the
additive and dominant models of inheritance, but statis-
tical significance was lost after adjustment. On the other
hand, homozygotes for the minor alleles of rs1800787
and rs1800789 SNPs in FGB gene exhibited a decreased
risk of CAD remaining statistically significant after
adjustment for confounding factors.
Haplotype analysis showed that when FGA and FGG
gene SNPs were considered together, FGA-FGG-H3
haplotype TGATTA bearing the minor alleles of both
rs2070006 and rs2066865 SNPs was associated with an
increase in disease risk in the unadjusted analysis, but
after adjustment this association disappeared.
Table 3 Results from logistic regression analysis for SNPs with significant associations before adjustment.
GENE SNP Genotype frequency Minor allele
frequency
Model OR;95% CI P-value adjusted OR; 95% CI
a adjusted P-value
a
Cases Controls Cases Controls
AA 0.36 0.46 Additive 1.26;1.00-1.59 0.055 1.26;0.97-1.63 0.081
FGA rs2070006 AG 0.51 0.41 0.39 0.34 Dominant 1.51;1.09-2.09 0.013 1.39;0.97-1.99 0.077
GG 0.13 0.13 Recessive 1.07;0.67-1.70 0.788 1.28;0.77-2.14 0.336
GG 0.56 0.58 Additive 0.92; 0.71-1.19 0.514 0.88;0.66-1.17 0.376
FGB rs1800789 GA 0.39 0.33 0.24 0.26 Dominant 1.06; 0.77-1.46 0.733 1.00;0.70-1.44 0.990
AA 0.05 0.09 Recessive 0.47; 0.24-0.92 0.026 0.42;0.19-0.90 0.026
CC 0.58 0.55 Additive 0.83; 0.64-1.07 0.153 0.77;0.58-1.03 0.076
FGB rs1800787 CT 0.37 0.36 0.24 0.27 Dominant 0.89; 0.65-1.23 0.473 0.81;0.57-1.16 0.254
TT 0.05 0.09 Recessive 0.50; 0.26-0.96 0.039 0.44;0.21-0.94 0.034
GG 0.61 0.70 Additive 1.31;0.99-1.75 0.062 1.32;0.97-1.80 0.077
FGG rs2066865 GA 0.34 0.26 0.21 0.17 Dominant 1.40;1.00-1.97 0.051 1.42;0.98-2.07 0.066
AA 0.05 0.04 Recessive 1.31;0.59-2.93 0.513 1.35;0.58-3.12 0.486
Results from logistic regression analysis for FGA, FGB and FGG gene SNPs that were significantly associated with disease, before adjustment for confounding
variables.
a adjustment for age, sex and the presence of hypercholesterolemia, hypertension, diabetes and smoking
Theodoraki et al. BMC Medical Genetics 2010, 11:28
http://www.biomedcentral.com/1471-2350/11/28
Page 4 of 7Therefore, our results do not reveal an important role
of FGA and FGG gene SNPs and FGA, FGB, FGG and
FGA-FGG haplotypes in CAD occurrence and are in
accordance with previously published data. The initial
associations published by Mannila et al. [12-14] support-
ing a role of FGG-FGA and FGG-FGB haplotypes in
myocardial infarction risk have not been replicated by
other investigators that studied single SNPs and haplo-
types in FGA, FGB and FGG genes in MI or CAD phe-
notypes [15-18].
Rs1800790 SNP in FGB gene was shown to be asso-
ciated with decreased MI risk applying the recessive
model in a meta-analysis [29]. Recently, the same SNP
was found to exert protective effect against premature
myocardial infarction in a Greek population [30]. In
our study we could not replicate these findings.
Interestingly, we found rs1800787 and rs1800789 var-
iants, that are highly correlated with rs1800790 (r
2 =
0.943 and r
2 = 0.928, respectively), to decrease disease
risk by about 50%, when modeled recessively. One could
hypothesize that the effect of rs1800790, found in the
previous studies, is attributed to the strong LD with
SNPs rs1800787 and/or rs1800789 - these two tightly
linked SNPs most likely are representing the same signal
of association with the disease and either of these SNPs
might be the functional one. Previous studies that
included these SNPs, or others that are in strong LD
with them, resulted in negative findings, but in those
studies the effect of the SNPs in the recessive model
was not considered [15,16].
Our study is limited by the small sample size. A pos-
terior analysis revealed that the power of our sample to
Table 4 Haplotypes for FGA, FGB, FGG and FGA-FGG gene SNPs with frequencies >5%.
SNPs
Haplotypes rs2070006 rs2070022 rs2070016 rs1800792 rs1118823 rs2066865 rs1800787 rs1800789 rs1800790 rs4681 rs4220
FGA-H1 T GA
FGA-H2 C G A
FGA-H3 C G G
FGA-H4 C A A
FGG-H1 C TG
FGG-H2 T A G
FGG-H3 T T A
FGB-H1 CGG CG
FGB-H2 TAA TA
FGA-FGG-H1 C G A C TG
FGA-FGG-H2 C G GCTG
FGA-FGG-H3 T GATTA
FGA-FGG-H4 C A ATA G
FGA-FGG-H5 T AGT A G
Bold and underlined letters indicate SNP minor alleles.
Table 5 Frequencies, ORs and 95% CIs for CAD in relation to the most frequent haplotypes.
Haplotype Controls (%) Cases (%) OR;95%CI P-value adjusted OR;95%CI
a adjusted P-value
a
FGA-H1 33.00 38.13 referent referent
FGA-H2 28.88 26.25 0.80;0.60-1.05 0.104 0.81;0.59-1.11 0.186
FGA-H3 21.10 20.27 0.84;0.62-1.14 0.256 0.75;0.53-1.07 0.111
FGA-H4 16.20 14.65 0.78;0.55-1.11 0.164 0.84;0.56-1.26 0.396
FGG-H1 48.84 45.16 referent referent
FGG-H2 32.78 32.81 1.06;0.83-1.36 0.638 1.13;0.86-1.50 0.387
FGG-H3 16.55 20.78 1.31;0.97-1.77 0.078 1.31;0.93-1.87 0.122
FGB-H1 72.34 75.37 referent referent
FGB-H2 21.84 20.77 0.92;0.71-1.20 0.547 0.89;0.65-1.21 0.463
FGA-FGG-H1 26.00 23.97 referent referent
FGA-FGG-H2 19.50 18.31 1.05;0.76-1.45 0.771 0.94;0.65-1.37 0.755
FGA-FGG-H3 15.71 20.08 1.42;1.02-1.98 0.040 1.38;0.94-2.02 0.098
FGA-FGG-H4 15.85 14.60 1.03;0.71-1.48 0.893 1.09;0.72-1.66 0.665
FGA-FGG-H5 14.03 15.28 1.22;0.86-1.75 0.264 1.21;0.79-1.84 0.381
a adjustment for age, sex and the presence of hypercholesterolemia, hypertension, diabetes and smoking
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on minor allele frequency, with significance level alpha
0.05. We cannot exclude the possibility of a modest
effect of SNPs or haplotypes in disease predisposition
that would possibly be apparent in a larger sample.
Nevertheless, our sample size is similar to that of Man-
nila et al. that studied eight fibrinogen SNPs in 377
post-infarction patients and 387 healthy individuals and
found that fibrinogen haplotypes, and not SNPs, were
associated with the risk of MI [14].
Another important limitation of our study is the lack
of information concerning the effect of SNPs or haplo-
types on fibrinogen levels. Moreover, we have not taken
into account the effect of proinflammatory markers,
such as IL-6, that have been shown to modify the effect
of SNPs on fibrinogen levels [26], and possibly the effect
of SNPs in disease risk. Nevertheless, in the multivariate
analysis we have adjusted our models for the presence
of obesity, hypertension, hypercholesterolemia and dia-
betes that represent in a way the proinflammatory status
and may partially compensate for the lack of informa-
tion for the levels of specific inflammatory markers.
The results of our study should be interpreted with
caution, taking into account the multiple tests per-
formed. If we applied the conservative Bonferroni’s cor-
rection then the level of statistical significance should be
0.001 and none of our associations would remain signifi-
cant. Nevertheless, the fact that rs1800787 and
rs1800789 are highly correlated with rs1800790 that has
been previously associated with disease increases our
confidence for our results.
Futhermore, we cannot exclude the possibility of mis-
classification of subjects with silent CAD in the control
group among subjects that were not subjected to coron-
ary angiography or stress test and who reported absence
of symptoms of disease. Finally, cases with fatal MI were
not included. Thus, we cannot rule out the possibility
that this polymorphism may predispose for more severe
disease phenotypes.
Conclusions
The results of the present study suggest that FGA and
FGG variants as well as FGA, FGB, FGG and FGA-FGG
haplotypes do not seem to be important contributors to
CAD occurence in our Greek population. Nevertheless,
FGB rs1800787 and rs1800789 variants, in the recessive
model, seem to confer protection to disease onset lower-
ing the risk by about 50%.
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